PVX-410: Phase I/IIa started

OncoPep began an open-label, dose-escalation, U.S. Phase I/IIa trial to evaluate 6 subcutaneous injections of 0.4 or 0.8 mg PVX-410 given every other week in combination with intramuscular Hiltonol (...